The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism
Open accessAbstract
Most human immunodeficiency virus type 1 (HIV-1) strains require either the CXCR4 or CCR5 chemokine receptor to efficiently enter cells. Blocking viral binding to these coreceptors is an attractive therapeutic target. Currently, several coreceptor antagonists are being evaluated in clinical trials that require characterization of coreceptor tropism for enrollment. In this report, we describe the development of an automated and accurate procedure for determining HIV-1 coreceptor tropism (Trofile) and its validation for routine laboratory testing. HIV-1 pseudoviruses are generated using full-length env genes derived from patient virus populations. Coreceptor tropism is determined by measuring the abilities of these pseudovirus populations to efficiently infect CD4 + /U87 cells expressing either the CXCR4 or CCR5 coreceptor. Viruses exclusively and efficiently infecting CXCR4 + /CD4 + /U87 cells are designated X4-tropic. Conversely, viruses exclusively and efficiently infecting CCR5 + /CD4 + /U87 cells are designated R5-tropic. Viruses capable of infecting both CXCR4 + /CD4 + /U87 and CCR5 + /CD4 + /U87 cells are designated dual/mixed-tropic. Assay accuracy and reproducibility were established by evaluating the tropisms of well-characterized viruses and the variability among replicate results from samples tested repeatedly. The viral subtype, hepatitis B virus or hepatitis C virus coinfection, and the plasma viral load did not affect assay performance. Minority subpopulations with alternate tropisms were reliably detected when present at 5 to 10%. The plasma viral load above which samples can be amplified efficiently in the Trofile assay is 1,000 copies per ml of plasma. Trofile has been automated for high-throughput use; it can be used to identify patients most likely to benefit from treatment regimens that include a coreceptor inhibitor and to monitor patients on treatment for the emergence of resistant virus populations that switch coreceptor tropism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor
Feng, Y., Broder, C. C., Kennedy, P. E., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5263.872 · Cited by 4,172
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
Dalgleish, A. G., Beverley, P. C. L., Clapham, P. R., Crawford, D. H., Greaves, M. F., & Weiss, R. A. (1984) · Nature · doi:10.1038/312763a0 · Cited by 3,533
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., & Martin, M. A. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,834
The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., Wu, L., Mackay, C. R., LaRosa, G., Newman, W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81313-6 · Cited by 2,287
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease
Berger, E. A., Murphy, P. M., & Farber, J. M. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.657 · Cited by 2,180
A REVIEW OF GOODNESS OF FIT STATISTICS FOR USE IN THE DEVELOPMENT OF LOGISTIC REGRESSION MODELS1
LEMESHOW, S., & HOSMER, D. W. (1982) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113284 · Cited by 1,947
Development of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196 · cited 2×
“To minimize the potential for generation of replication-competent virus upon cotransfection of target cells with eETV libraries, a self-inactivating deletion in the U3 region of the 3 long terminal repeat (LTR) (U3) was introduced that substantially reduces viral-gene transcription from the 5 LTR of an integrated prov…”
BackgroundCD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
Wu, L., Gerard, N. P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N., Borsetti, A., Cardoso, A. A., Desjardin, E., Newman, W., et al. (1996) · Nature · doi:10.1038/384179a0 · Cited by 1,167
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes
Bleul, C. C., Wu, L., Hoxie, J. A., Springer, T. A., & Mackay, C. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1925 · Cited by 1,134
Schuitemaker, H., Koot, M., Kootstra, N. A., Dercksen, M. W., de Goede, R. E., van Steenwijk, R. P., Lange, J. M., Schattenkerk, J. K., Miedema, F., & Tersmette, M. (1992) · Journal of Virology · doi:10.1128/jvi.66.3.1354-1360.1992 · Cited by 1,032
A Conserved HIV gp120 Glycoprotein Structure Involved in Chemokine Receptor Binding
Rizzuto, C. D., Wyatt, R., Hernández-Ramos, N., Sun, Y., Kwong, P. D., Hendrickson, W. A., & Sodroski, J. (1998) · Science · doi:10.1126/science.280.5371.1949 · Cited by 812
Koot, M., Keet, I. P. M., Vos, A. H. V., de Goede, R. E. Y., Roos, M. T. L., Coutinho, R. A., Miedema, F., Schellekens, P. T. A., & Tersmette, M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-9-199305010-00004 · Cited by 785
Molecular Cloning and Functional Expression of a New Human CC-Chemokine Receptor Gene
Samson, M., Labbe, O., Mollereau, C., Vassart, G., & Parmentier, M. (1996) · Biochemistry · doi:10.1021/bi952950g · Cited by 686
A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y., Wrin, T., Huang, W., Tian, H., Smith, D., Winslow, G. A., Capon, D. J., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.920-928.2000 · Cited by 646
Self-citationTersmette, M., Gruters, R. A., de Wolf, F., de Goede, R. E., Lange, J. M., Schellekens, P. T., Goudsmit, J., Huisman, H. G., & Miedema, F. (1989) · Journal of Virology · doi:10.1128/jvi.63.5.2118-2125.1989 · Cited by 636
TERSMETTE, M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92628-7 · Cited by 575
Major Glycoprotein Antigens That Induce Antibodies in AIDS Patients Are Encoded by HTLV-III
Allan, J. S., Coligan, J. E., Barin, F., McLane, M. F., Sodroski, J. G., Rosen, C. A., Haseltine, W. A., Lee, T. H., & Essex, M. (1985) · Science · doi:10.1126/science.2986290 · Cited by 572
Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins
Gelderblom, H. R., Hausmann, E. H. S., Özel, M., Pauli, G., & Koch, M. A. (1987) · Virology · doi:10.1016/0042-6822(87)90449-1 · Cited by 521
Cocchi, F., DeVico, A. L., Garzino-Demo, A., Cara, A., Gallo, R. C., & Lusso, P. (1996) · Nature Medicine · doi:10.1038/nm1196-1244 · Cited by 495
Fätkenheuer, G., Pozniak, A. L., Johnson, M. A., Plettenberg, A., Staszewski, S., Hoepelman, A. I. M., Saag, M. S., Goebel, F. D., Rockstroh, J. K., Dezube, B. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1319 · Cited by 495
Reeves, J. D., Gallo, S. A., Ahmad, N., Miamidian, J. L., Harvey, P. E., Sharron, M., Pöhlmann, S., Sfakianos, J. N., Derdeyn, C. A., Blumenthal, R., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252469399 · Cited by 404
Robey, W. G., Safai, B., Oroszlan, S., Arthur, L. O., Gonda, M. A., Gallo, R. C., & Fischinger, P. J. (1985) · Science · doi:10.1126/science.2984774 · Cited by 349
Westby, M., Lewis, M., Whitcomb, J., Youle, M., Pozniak, A. L., James, I. T., Jenkins, T. M., Perros, M., & van der Ryst, E. (2006) · Journal of Virology · doi:10.1128/jvi.80.10.4909-4920.2006 · Cited by 337
Self-citationHIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
Trkola, A., Kuhmann, S. E., Strizki, J. M., Maxwell, E., Ketas, T., Morgan, T., Pugach, P., Xu, S., Wojcik, L., Tagat, J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012519099 · Cited by 303
Speck, R. F., Wehrly, K., Platt, E. J., Atchison, R. E., Charo, I. F., Kabat, D., Chesebro, B., & Goldsmith, M. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.9.7136-7139.1997 · Cited by 275
Cormier, E. G., & Dragic, T. (2002) · Journal of Virology · doi:10.1128/jvi.76.17.8953-8957.2002 · Cited by 251
Si, Z., Madani, N., Cox, J. M., Chruma, J. J., Klein, J. C., Schön, A., Phan, N., Wang, L., Biorn, A. C., Cocklin, S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307953101 · Cited by 247
Epidemiology and Predictive Factors for Chemokine Receptor Use in HIV‐1 Infection
Moyle, G. J., Wildfire, A., Mandalia, S., Mayer, H., Goodrich, J., Whitcomb, J., & Gazzard, B. G. (2005) · The Journal of Infectious Diseases · doi:10.1086/428096 · Cited by 230
Self-citationTrkola, A., Ketas, T. J., Nagashima, K. A., Zhao, L., Cilliers, T., Morris, L., Moore, J. P., Maddon, P. J., & Olson, W. C. (2001) · Journal of Virology · doi:10.1128/jvi.75.2.579-588.2001 · Cited by 224
Strizki, J. M., Tremblay, C., Xu, S., Wojcik, L., Wagner, N., Gonsiorek, W., Hipkin, R. W., Chou, C.-C., Pugliese-Sivo, C., Xiao, Y., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.4911-4919.2005 · Cited by 213
Self-citationKuhmann, S. E., Pugach, P., Kunstman, K. J., Taylor, J., Stanfield, R. L., Snyder, A., Strizki, J. M., Riley, J., Baroudy, B. M., Wilson, I. A., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.2790-2807.2004 · Cited by 196
HIV entry inhibitors: mechanisms of action and resistance pathways
Briz, V., Poveda, E., & Soriano, V. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl027 · Cited by 185
Pastore, C., Nedellec, R., Ramos, A., Pontow, S., Ratner, L., & Mosier, D. E. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.750-758.2006 · Cited by 160
Rizzuto, C. D., & Sodroski, J. (2000) · AIDS Research and Human Retroviruses · doi:10.1089/088922200308747 · Cited by 159
KUIKEN, C. L., & Foley, B. T. (2000) · doi:10.2172/1186021 · Cited by 133
Jekle, A., Keppler, O. T., Clercq, E. D., Schols, D., Weinstein, M., & Goldsmith, M. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.10.5846-5854.2003 · Cited by 129
Intrinsic Obstacles to Human Immunodeficiency Virus Type 1 Coreceptor Switching
Pastore, C., Ramos, A. G., & Mosier, D. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.14.7565-7574.2004 · Cited by 128
Reeves, J. D., Miamidian, J. L., Biscone, M. J., Lee, F.-H., Ahmad, N., Pierson, T. C., & Doms, R. W. (2004) · Journal of Virology · doi:10.1128/jvi.78.10.5476-5485.2004 · Cited by 113
Trouplin, V., Salvatori, F., Cappello, F., Obry, V., Brelot, A., Heveker, N., Alizon, M., Scarlatti, G., Clavel, F., & Mammano, F. (2001) · Journal of Virology · doi:10.1128/jvi.75.1.251-259.2001 · Cited by 113
Esté, J. A., Cabrera, C., Clercq, E. D., Struyf, S., Damme, J. V., Bridger, G. J., Skerlj, R. T., Abrams, M. J., Henson, G. W., Gutiérrez, A., et al. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23157-6 · Cited by 101
Co-receptor antagonists as HIV-1 entry inhibitors
Shaheen, F., & Collman, R. G. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200402000-00003 · Cited by 81
Japour, A. J., Fiscus, S. A., Arduino, J. M., Mayers, D. L., Reichelderfer, P. S., & Kuritzkes, D. R. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.9.2291-2294.1994 · Cited by 77
Chemokines and coreceptors in HIV/SIV-host interactions.
Tl, H., & Doms, R. W. (1998) · PubMed · Cited by 67
Cited by
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803152 · Cited by 752
Hirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection
Fätkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I. M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803154 · Cited by 364
HIV-1 drug resistance and resistance testing
Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.08.031 · Cited by 333
Metadata
- Authors
- Whitcomb, J. M., Huang, W., Fransen, S., Limoli, K., Toma, J., Wrin, T., Chappey, C., Kiss, L. D. B., Paxinos, E. E., & Petropoulos, C. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-02
- Volume
- 51
- Issue
- 2
- Pages
- 566-575
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2169054534
- Cited by
- 356
- References
- 45
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.